###### Strengths and limitations of this study

-   This study provides a real insight into the current status of medication adherence rates among patient with type 2 diabetes mellitus (T2DM) in Saudi Arabia.

-   Using real-world data of more than 5000 patients with T2DM in Saudi Arabia, the study assesses the impact of adherence among different patient subgroups.

-   This study did not control the severity of diabetes or diabetes complications, which may affect the rate of adherence to oral antidiabetic drugs (OADs).

-   This study indirectly measured adherence to OADs using patient electronic health records, which may not reflect the actual adherence rate.

-   Findings from this study cannot be generalised to different populations and settings.

Introduction {#s1}
============

Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic progressive disorder characterised by high glucose levels in the blood.[@R1] The estimated global prevalence in the adult population was 8.8% in 2015[@R2] and is projected to increase to 10.4% by 2040.[@R2] In Saudi Arabia, the estimated prevalence of T2DM is approximately 23%[@R3] with another 25.5% of the population (30 years and older) classified as pre-diabetes. By 2035, the prevalence of T2DM in Saudi Arabia is projected to double and is expected to reach an estimated 7.5 million cases.[@R5] While diabetes is projected to be the seventh leading cause of mortality and disability worldwide by 2030,[@R6] it is already the sixth leading cause of death in Saudi Arabia based on the WHO report.[@R7] It is well established that uncontrolled T2DM is associated with negative health consequences such as blindness, kidney failure, lower limb amputation and other complications, all of which result in poor quality of life in patients.[@R8] Also, T2DM is a well-established risk factor for cardiovascular disease (CVD) and macrovascular complications including costly conditions like coronary heart disease, stroke, nephropathy, retinopathy and others.[@R10] A meta-analysis concluded that the risk of CVD in patients with diabetes was three times compared with those without diabetes.[@R11]

Worldwide, diabetes imposes a large economic burden on the individuals and national healthcare systems. A recent study estimated the global cost of diabetes in adult patients at US\$1.31 trillion, which represents 1.8% of the global gross domestic product.[@R12] Two-third of this cost was direct medical cost while the remaining one-third was attributable to indirect cost such as loss in productivity.[@R12] In the Middle East and North Africa regions, the rising prevalence of diabetes is projected to increase the healthcare cost by 67% by 2045.[@R3] Similar trends are being observed in Saudi Arabia as well and the medical healthcare expenditure for people with diabetes is 10 times higher (US\$3686 vs US\$380) than those without the condition.[@R13] Diabetes and its complications also result in high indirect costs such as costs related to absenteeism, loss of productivity, disability and premature mortality. The overall economic burden of diabetes in Saudi Arabia is substantial with an estimated direct cost of 17 billion Saudi Riyals (US\$4.5 billion) in 2014, which is expected to increase to 43 billion Saudi Riyals (US\$11.4 billion) in the future.[@R14]

Patient adherence to recommended treatment regimen is one of the key contributors to quality health outcomes in T2DM. The benefits of drug therapy in terms of improved glycaemic control and subsequent reduction in microvascular, macrovascular complications and morbidity have been fairly demonstrated. Adherence to oral antidiabetic drugs (OADs) is associated with better glycaemic control,[@R15] reduced risk of diabetes complications and reduced economic burden.[@R17] Investigators in Spain reported that a change in glycated haemoglobin (HbA1c) between the first and last patient visits was largely driven by OADs adherence in 13% of the cases.[@R19] In Saudi Arabia, nearly 56% of patients have been shown to have low medication adherence.[@R20]

Although poor adherence (medication underuse) is a well-recognised issue in any healthcare setting, having excess supply of medications than needed (medication oversupply) may also lead to negative health outcomes such as increase in toxicity risks, inefficient use of available healthcare resources and increase in unnecessary healthcare costs.[@R21] Prevalence of oversupply has been shown to vary across different institutions, medication classes and countries and ranges from 11% to 53%.[@R22] Medication oversupply was common, especially among T2DM patients, which may increase the risk of hospitalisation[@R23] and further influence achieving the recommended level of HbA1c.[@R27]

With the prevalence of T2DM increasing at an alarming rate in Saudi Arabia, there is an urgent need to address non-adherence to positive interventions, such as OADs, so as to reign in the rapid escalation of healthcare costs and improve patient outcomes. Although several studies have measured the adherence and oversupply rate in patients with diabetes, their prevalence among patients with T2DM in Saudi Arabia along with their impact on glycaemic control is largely unknown.[@R28] The purpose of this study was to evaluate adherence to OADs and to explore the variables associated with OADs non-adherence in patients with type 2 diabetes. The association between glycaemic control and adherence to OADs will also be examined.

Methods {#s2}
=======

Study design and setting {#s2a}
------------------------

A retrospective study was conducted in King Saud University Medical City (KSUMC), the largest tertiary teaching hospital located in the central region of Saudi Arabia. KSUMC is equipped with more than 1200 beds and provides a wide array of medical services. The patient population is composed mainly of Saudi citizens who are predominantly residents of the capital city Riyadh but the hospital also serves as a referral centre for the whole country. The study was approved by the institutional review board (IRB) at KSUMC (IRB number: E-16-2203).

Data sources {#s2b}
------------

Patients with a recorded diagnosis of T2DM (using International Classifications of Diseases---ninth edition, Clinical Modification codes) and receiving OADs at outpatient clinics of KSUMC were retrospectively identified from the electronic health records (EHRs) for the period 1 January--30 December 2016. The extracted data included demographic information (age, gender, marital status, nationality), laboratory data (HbA1c) and prescription data (name of prescription filled; dispensing date; quantity of drug; number of days supplied and refills). All the data were extracted from the EHRs and there was no direct involvement of any patient in the study. Patient consent was therefore not required and all study variables were collected retrospectively and anonymously (de-identified data) from EHRs.

Study population {#s2c}
----------------

Patients aged 18 years and older with T2DM who had received their treatment at outpatient clinics at KSUMC during the study period had at least two prescription fills for one of the following OADs: sulfonylureas (glibenclamide); biguanides (metformin), thiazolidinediones (pioglitazone), meglitinide analogues (repaglinide), glucosidase inhibitor (acarbose), oral dipeptidyl peptidase-4 inhibitor (sitagliptin) and combination therapy were included in the study. Patients on insulin or incretin mimetics (liraglutide injection) and those without at least one HbA1C value were excluded from this study.

Patient and public involvement {#s2d}
------------------------------

Patients and public were not involved in the design or conduct of this study.

Outcome measures {#s3}
================

Primary outcome: adherence to OADs {#s3a}
----------------------------------

The modified medication possession ratio (mMPR) was used as a proxy to measure the adherence rate in this study. The mMPR was chosen as it is one of the most commonly reported adherence assessment method using EHRs and administrative claims data in the literature.[@R24] Also, as one of the aims of this study is to estimate the oversupply rate, mMPR allows for calculation of medication oversupply over 100% while in other assessment methods such as the proportion of days covered, any medication oversupply (over 100%) is truncated.[@R36] The mMPR was calculated as the sum of the total days supply for all OADs fills divided by the sum of the number of days covered and the last refill days.[@R18] [@R19] The date of the first prescription fill was designated as the index date. The total days supplied for each OAD was calculated from the index date until the end of 2016. Patients were considered adherent to their medication regimen if the estimated mMPR ≥0.8. Otherwise, the patients were deemed as poorly adherent. An mMPR value greater than 1 indicated that the patients filled their medications early before entirely consuming their preceding stock of medications; thus, they had excessive medications than needed. Medication oversupply was defined as mMPR [\>]{.ul}1.2; the cut-off point of 20% difference in supply has been reported as an acceptable range in several studies.[@R23] In this study, adherence was categorised into: poor adherence (mMPR \<0.8), good adherence (mMPR [\>]{.ul}0.8 to \<1.2) and oversupply (mMPR [\>]{.ul}1.2).[@R37] The mMPR was calculated separately for each OAD prescribed during the 12-month study period. Then, an average mMPR was calculated with equal weighting of each drug class.

Secondary outcome: association between OADs adherence and glycaemic control {#s3b}
---------------------------------------------------------------------------

The secondary outcome of glycaemic control was based on the patient's last HbA1c reading. The American Diabetes Association Standards of Care has recommended that HbA1c\<7% should be the glycaemic goal for adults with T2DM.[@R38] Using this threshold, the HbA1c was classified into two categories: \<7% indicating good glycaemic control and [\>]{.ul}7% indicating poor glycaemic control. The last HbA1c reading was used to determine the relationship between adherence and glycaemic control.

Independent variables {#s3c}
---------------------

Independent variables included age groups, gender, marital status, nationality and diagnosed comorbid chronic conditions (hypertension, heart failure, ischaemic heart disease, dyslipidaemia, cancer, chronic kidney disease, asthma, osteoarthritis, osteoporosis, depression and anxiety).[@R39] In addition, polypharmacy was calculated for each patient in this study. Although there is no consensus on the threshold regarding the number of medications used by patients to be considered as polypharmacy, the most accepted definition of polypharmacy is the use of five or more drugs.[@R41] Based on this threshold, polypharmacy was categorised as hyperpolypharmacy (≥10 medications), major polypharmacy (5--9 medications) and minor polypharmacy (2--4 medications).

Statistical analysis {#s3d}
--------------------

Descriptive statistics (frequency and percentages) were used to summarise the categorical variables (sex, marital status, nationality, polypharmacy and co-existing chronic conditions) and means and SD were calculated for continuous variables (age). Χ^2^ tests were utilised to determine the factors associated with adherence and only significant factors were used in the regression models. The factors associated with non-adherence and medication oversupply were assessed using multinomial logistic regression models after adjusting for independent variables (age, gender, nationality, marital status and co-existing chronic conditions). The multinomial logistic regression is an extension of binomial logistic regression to allow for a dependent variable with more than two categories of the outcome measure (eg, good adherence, poor adherence and oversupply). All statistical analyses were conducted using the Statistical Analysis Software V.9.2 and an a priori significance level was set at [p\<]{.ul}0.05.

Results {#s4}
=======

A total of 5457 patients with T2DM were identified for year 2016 with a majority of them being women (n=3400, 62.3%) and adults 60 years and older (n=2358; 43.2%). More than half of the sample had co-existing chronic conditions, with hypertension (65.6%) and dyslipidaemia (66.0%) being the most common conditions. Around 59.8% of patients had major polypharmacy with 18.7% having hyperpolypharmacy. The average HbA1c was 8.2±1.67. [Table 1](#T1){ref-type="table"} presents the demographic and clinical characteristics of the study population. Overall, the vast majority (89.2%) of adults with T2DM were using metformin followed by sitagliptin (23.5%), glibenclamide (16.5%) and pioglitazone (12.1%) ([table 2](#T2){ref-type="table"}).

###### 

Characteristics of the study population and number and row percentage of characteristics by adherence level among adults with diabetes

                             Total         Poor adherence   Good adherence   Medication oversupply   Sign.                                    
  -------------------------- ------------- ---------------- ---------------- ----------------------- ------- ------ ------- ------ ---------- --------
  Total                      5457          100.0            2337             42.8                    2652    48.6   468.0   8.6               
  Age mean (SD)              58.2 (10.8)   57.8 (11.0)      58.5 (10.6)      58.3 (10.8)                                                      
  Age groups                                                                                                                       0.089      
   18--29                    39            0.7              15               38.5                    20      51.3   4.0     10.3              
   30--39                    220           4.0              107              48.6                    96      43.6   17.0    7.7               
   40--49                    759           13.9             362              47.7                    338     44.5   59.0    7.8               
   50--59                    2081          38.1             884              42.5                    1017    48.9   180.0   8.6               
   =\>60                     2358          43.2             969              41.1                    1181    50.1   208.0   8.8               
  Marital status                                                                                                                   0.099      
   Single                    480           9.4              186              38.8                    244     50.8   50.0    10.4              
   Married                   4604          90.6             1981             43.0                    2242    48.7   381.0   8.3               
  Gender                                                                                                                           \<0.0001   \*\*\*
   Male                      2057          37.7             801              38.9                    1066    51.8   190.0   9.2               
   Female                    3400          62.3             1536             45.2                    1586    46.6   278.0   8.2               
  Nationality                                                                                                                      \<0.0001   \*\*\*
   Saudi                     4830          88.7             2105             43.6                    2335    48.3   390.0   8.1               
   Non-Saudi                 613           11.3             227              37.0                    308     50.2   78.0    12.7              
  Obesity                                                                                                                          0.542      
   Yes                       437           8.0              180              41.2                    223     51.0   34.0    7.8               
   No                        5020          92.0             2157             43.0                    2429    48.4   434.0   8.6               
  Hypertension                                                                                                                     0.340      
   Yes                       3581          65.6             1513             42.3                    1766    49.3   302.0   8.4               
   No                        1876          34.4             824              43.9                    886     47.2   166.0   8.8               
  Dyslipidaemia                                                                                                                    0.030      \*
   Yes                       3603          66.0             1556             43.2                    1764    49.0   283.0   7.9               
   No                        1854          34.0             781              42.1                    888     47.9   185.0   10.0              
  Heart failure                                                                                                                    0.005      \*\*
   Yes                       33            0.6              13               39.4                    12      36.4   8.0     24.2              
   No                        5424          99.4             2324             42.8                    2640    48.7   460.0   8.5               
  Ischaemic heart disease                                                                                                          \<0.0001   \*\*\*
   Yes                       161           3.0              67               41.6                    67      41.6   27.0    16.8              
   No                        5296          97.0             2270             42.9                    2585    48.8   441.0   8.3               
  Chronic kidney disease                                                                                                           0.017      \*
   Yes                       37            0.7              14               37.8                    15      40.5   8.0     21.6              
   No                        5420          99.3             2323             42.9                    2637    48.7   460.0   8.5               
  Cancer                                                                                                                           0.961      
   Yes                       63            1.2              27               42.9                    30      47.6   6.0     9.5               
   No                        5394          98.8             2310             42.8                    2622    48.6   462.0   8.6               
  Asthma                                                                                                                           0.949      
   Yes                       571           10.5             244              42.7                    276     48.3   51.0    8.9               
   No                        4886          89.5             2093             42.8                    2376    48.6   417.0   8.5               
  Osteoarthritis                                                                                                                   0.009      \*\*
   Yes                       373           6.8              140              37.5                    187     50.1   46.0    12.3              
   No                        5084          93.2             2197             43.2                    2465    48.5   422.0   8.3               
  Osteoporosis                                                                                                                     0.189      
   Yes                       199           3.6              97               48.7                    89      44.7   13.0    6.5               
   No                        5258          96.4             2240             42.6                    2563    48.7   455.0   8.7               
  Anxiety                                                                                                                          0.001      \*\*
   Yes                       284           5.2              114              40.1                    129     45.4   41.0    14.4              
   No                        5173          94.8             2223             43.0                    2523    48.8   427.0   8.3               
  Depression                                                                                                                       0.640      
   Yes                       100           1.8              40               40.0                    49      49.0   11.0    11.0              
   No                        5357          98.2             2297             42.9                    2603    48.6   457.0   8.5               
  Polypharmacy                                                                                                                     \<0.0001   \*\*\*
   Hyperpolypharmacy         1019          18.7             387              38.0                    494     48.5   138.0   13.5              
   Major polypharmacy        3266          59.8             1444             44.2                    1584    48.5   238.0   7.3               
   Minor polypharmacy        1172          21.5             506              43.2                    574     49.0   92.0    7.8               
   Average HbA1C mean (SD)   8.2 (1.67)    8.1 (1.67)       8.2 (1.66)       8.3 (1.66)                                                       
  Glycaemic control                                                                                                                0.005      \*\*
   Good glycaemic control    1231          698              698              46.9                    671     45.1   119     8.0               
   Poor glycaemic control    4224          1076             1076             41.9                    1290    50.2   204     7.9               

Study population comprised of 5457 adults with type 2 diabetes mellitus.

mMPR, modified medication possession ratio; N, number; Sign., significance.

Asterisks (\*) represent significant differences based on mMPR from Χ^2^ tests.

\*\*\*p\<0.001; \*\*0.001≤p \<0.01; \*0.01≤p \<0.05.

###### 

Frequency and percentage of OADs and comparison between medication possession ratio, modified (mMPR)

                  N      \%     Mean adherence   SD     Poor adherence   Good adherence   Oversupply rate
  --------------- ------ ------ ---------------- ------ ---------------- ---------------- -----------------
  Acarbose        205    3.8    0.97             0.31   24.9%            58.1%            17.1%
  Metformin       4869   89.2   0.79             0.31   48.1%            43.3%            8.6%
  Glibenclamide   901    16.5   0.93             0.29   29.5%            56.6%            13.9%
  Sitagliptin     1285   23.5   0.92             0.27   28.9%            59.9%            11.2%
  Repaglinide     46     0.8    0.97             0.21   17.5%            71.7%            10.8%
  Pioglitazone    662    12.1   0.97             0.27   19.6%            65.0%            15.4%
  Combination     410    7.5    0.84             0.32   46.6%            43.9%            9.5%

Study population comprised of 5457 adults with type 2 diabetes mellitus.

mMPR, modified medication possession ratio; N, number; OADs, oral antidiabetic drugs.

OADs adherence {#s4a}
--------------

Among the study population, 48.6% had good adherence to OAD (mMPR \>0.8 to \<1.2), 42.8% had poor adherence (mMPR \<0.8) and 8.6% had medication oversupply (mMPR \>1.2) ([table 1](#T1){ref-type="table"}). A significantly higher rate of poor adherence was reported among women when compared with men (45.2% vs 38.9%, p value=0.0001). OADs oversupply was significantly higher among patients with heart failure (24.2%), ischaemic heart disease (16.8%), chronic kidney disease (21.6%), osteoarthritis (12.3%), anxiety (14.4%) and depression (11.0%) when compared with those without these comorbid conditions. Medication oversupply was also significantly higher among patients with hyperpolypharmacy when compared with those without polypharmacy (13.5% vs 7.8%, p value =0.0001). The medication oversupply rate was highest for acarbose (17.1%) followed by pioglitazone (15.4%) and glibenclamide (13.9%) ([table 2](#T2){ref-type="table"}).

OADs adherence and glycaemic control {#s4b}
------------------------------------

Results show that good adherence was highest among those who used repaglinide (71.0%) followed by pioglitazone (65.0%) and sitagliptin (59.0%) ([table 2](#T2){ref-type="table"}). Also, this study found no significant association between medication adherence with any OADs and glycaemic control ([table 3](#T3){ref-type="table"}). However, a higher rate of good glycaemic control (HbA1C\<7%) was observed among patients on metformin (24.1%) followed by combination therapy (12.0%) and pioglitazone (11.5%).

###### 

Association between adherence to OADs and glycaemic control

                                      Good glycaemic control   Poor glycaemic control   Χ^2^   P value   Sig             
  ----------------------------------- ------------------------ ------------------------ ------ --------- ------- ------- --
  Adherence to diabetic medications                                                                                      
  Acarbose                                                                                               0.912   0.634   
   Poor adherence                     7                        20                       28     80                        
   Good adherence                     15                       17.6                     70     82.4                      
   Oversupply                         3                        11.1                     24     88.9                      
  Metformin                                                                                              0.978   0.613   
   Poor adherence                     698                      39.2                     1084   60.8                      
   Good adherence                     601                      38                       980    62                        
   Oversupply                         113                      40.8                     164    59.2                      
  Glibenclamide                                                                                          0.151   0.927   
   Poor adherence                     35                       15.4                     193    84.6                      
   Good adherence                     68                       15.7                     366    84.3                      
   Oversupply                         15                       14.2                     91     85.8                      
  Sitaglibtin                                                                                            0.188   0.91    
   Poor adherence                     50                       19.5                     206    80.5                      
   Good adherence                     97                       18.3                     433    81.7                      
   Oversupply                         18                       18.2                     81     81.8                      
  Repaglinide                                                                                            0.625   0.732   
   Poor adherence                     2                        25                       6      75                        
   Good adherence                     5                        20                       20     80                        
   Oversupply                         0                        0                        2      100                       
  Pioglitazone                                                                                           0.52    0.771   
   Poor adherence                     19                       17.4                     90     82.6                      
   Good adherence                     70                       20.3                     275    79.7                      
   Oversupply                         14                       21.2                     52     78.8                      
  Combination therapy                                                                                    5.928   0.052   
   Poor adherence                     22                       15.8                     117    84.2                      
   Good adherence                     30                       23.6                     97     76.4                      
   Oversupply                         8                        36.4                     14     63.6                      

 Study population comprised of 5457 Adults with type 2 diabetes mellitus.

OADs: oral antidiabetic drugs; Sig., significance.

Factors associated with OADs adherence {#s4c}
--------------------------------------

The adjusted OR (AOR) and 95% CI from multinomial logistic regressions on adherence to OADs are presented in [table 4](#T4){ref-type="table"}. Several factors associated with OADs adherence were identified: gender, nationality, co-existing chronic conditions and polypharmacy. Women with T2DM were less likely to have good adherence (AOR=0.76, 95% CI=0.67, 0.86) compared with men. Medication oversupply was more likely among T2DM patients with hyperpolypharmacy (AOR=1.88, 95% CI=1.36, 2.63), comorbid osteoarthritis (AOR=1.72, 95% CI=1.20, 02.45) and non-Saudi patients (AOR=1.53, 95% CI=1.16, 2.01).

###### 

OR and 95% CIs from multinomial logistic regression on adherence among adults with type 2 diabetes mellitus

                               Good adherence   P value          Sig.       Medication oversupply   P value   Sig.                     
  ---------------------------- ---------------- ---------------- ---------- ----------------------- --------- ---------------- ------- ------
  Last HbA1C                                                                                                                           
   Good\<7%                    0.81             (0.70 to 1.10)   0.004                              0.90      (0.69 to 1.17)   0.434   
   Poor\>7%                                                                                                                            
   Gender                                                                                                                              
  Female                       0.76             (0.67 to 0.86)   \<0.0001   \*\*\*                  0.64      (0.49 to 0.83)   0.001   \*\*
   Male (Ref.)                                                                                                                         
  Nationality                                                                                                                          
   Non-Saudi                   1.15             (0.93 to 1.43)   0.218                              1.53      (1.16 to 2.01)   0.023   \*
   Saudi (Ref.)                                                                                                                        
  Ischaemic heart disease                                                                                                              
   Yes                         0.78             (0.48 to 1.28)   0.215                              1.37      (0.99 to 2.80)   0.287   
   No (Ref.)                                                                                                                           
  Heart failure                                                                                                                        
   Yes                         0.78             (0.34 to 1.71)   0.446                              1.77      (0.79 to 4.47)   0.343   
   No (Ref.)                                                                                                                           
  Dyslipidaemia                                                                                                                        
   Yes                         1.06             (0.94 to 1.21)   0.683                              0.83      (0.69 to 1.02)   0.270   
   No (Ref.)                                                                                                                           
  CKD                                                                                                                                  
   Yes                         0.78             (0.42 to 1.81)   0.756                              1.97      (0.79 to 4.48)   0.089   
   No (Ref.)                                                                                                                           
  Osteoarthritis                                                                                                                       
   Yes                         1.15             (0.92 to 1.81)   0.260                              1.72      (1.20 to 2.45)   0.008   \*\*
   No (Ref.)                                                                                                                           
  Anxiety                                                                                                                              
   Yes                         0.89             (0.64 to 1.25)   0.888                              1.41      (0.95 to 2.08)   0.072   
   No (Ref.)                                                                                                                           
  Polypharmacy                                                                                                                         
   Hyperpolypharmacy           1.11             (0.86 to 1.41)   0.176                              1.88      (1.36 to 2.63)   0.006   \*\*
   Major polypharmacy          1.04             (0.87 to 1.23)   0.459                              1.27      (0.98 to 1.64)   0.871   
   Minor polypharmacy (Ref.)                                                                                                           

Asterisks (\*) represent significant differences based on adherence from multinomial logistic regressions with poor adherence as the reference group.

\*\*\*p\<.001; \*\*.001≤p \<.01; \*.01≤p \<.05

Study population comprised of 5457 adults with type 2 diabetes mellitus.

CKD, chronic kidney disease; HbA1C, glycated haemoglobin; Ref., reference group; Sig., significance.

Discussion {#s5}
==========

Medication adherence {#s5a}
--------------------

Medication adherence is critical in the treatment of patients with diabetes. Failure to adhere to prescribed medication regimen is recognised as a serious issue resulting in negative consequences to the patient and the healthcare system as well. Thus, there is a need to identify specific barriers that will help in adapting appropriate tools to overcome and improve medication adherence.[@R35] The heterogeneity, complexity and importance of this issue have been extensively studied and well recognised in the literature.[@R35] Several barriers and facilitators of adherence have been identified including patient-related factors (belief and knowledge, cognitive function, health literacy), physician-related factors (communication with patient), medication-related factors (adverse drug reaction, drug regimen complexity, cost) and system-based factors (lack of medication review, lack of patient follow-up).[@R43] However, factors associated with non-adherence were not comprehensive and are reported to vary depending on the nature of the disease (eg, severity), patients' characteristics (eg, demographic and socioeconomic status).[@R46] To explore the issue of medication non-adherence in patients with T2DM in Saudi Arabia, this study utilised patients' refill data from EHRs of a tertiary hospital and estimated patients' overall adherence to OADs using mMPR values. The study found that almost half of the study population with T2DM had good adherence (mMPR \>0.8). In the published literature, good adherence has been shown to vary widely and results from a systematic review of 20 retrospective studies demonstrated that adherence to OADs therapy ranged from 36% to 93% in patients with diabetes.[@R47] These variations in adherence were affected by several factors including the adherence measurement tools, population or institution where the studies were conducted, and the medications included in the studies.[@R44]

The study findings also revealed that adherence varied widely across different medications with the highest adherence rates observed in patients on repaglinide followed by pioglitazone users and was lowest among metformin users. Several studies have demonstrated that patients on pioglitazone and sulfonylureas have a greater adherence rate than those on metformin.[@R48] The side effects of metformin such as flatulence and diarrhoea can possibly be the cause of poor adherence rates among patients.[@R49] In this study, women were less likely to be adherent as compared with men, which was not consistent with previous studies that showed women having signiﬁcantly higher adherence rates than men.[@R50] However, few studies have demonstrated similar surprising findings in which women have low level of adherence.[@R53] Some reason reported in the literature indicated that women often prescribed more medication, have a complex medications regimen and experience more side effects which could contribute to lower rates of adherence.[@R56] Although the actual reason behind these differences in adherence level between men and women warrants further investigation, these differences should be considered in personalised treatment plan in order to improve adherence rate and clinical outcomes.[@R56]

Medication oversupply {#s5b}
---------------------

Another interesting study finding was related to medication oversupply; around 8.6% of the patients had medication oversupply, in particular, among those with chronic kidney disease and patients with hyperpolypharmacy. In addition to the significant economic burden associated with excessive supply of medications, oversupply of diabetes medications may result in accidental medication errors, which can possibly lead to negative outcomes.[@R57] The current study results are consistent with the published studies that reported medication oversupply range from 6.7% to 13.4%.[@R23] Medication oversupply could be a result of a number of factors such as sicker patients, medication management system issues, poor medication reconciliation, patients visiting multiple clinicians and miscommunication between the patients and their clinicians.[@R25] It should be noted that KSUMC utilises a 90-day supply for chronic disease, which has been previously reported as being more convenient to the patient and can improve patient adherence. However, it can also increase the chance of the patient having an excess amount of medication, which can lead to oversupply and wastage. This is especially the case when the treatment regimen of a patient has been switched or changed.[@R58]

Relationship between adherence to OADs and glycaemic control {#s5c}
------------------------------------------------------------

There is compelling data to show that glycaemic control is essential in the management of T2DM and it dramatically reduces diabetes-related complications. In the UK Prospective Diabetes Study (UKPDS) trial, the microvascular complication rate was reduced by 25% and myocardial infarction (MI) by 16% in the intensive treatment arm.[@R60] A meta-analysis of the four diabetes trials, Action to Control Cardiovascular Risk in Diabetes, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, UKPDS and Veterans Affairs Diabetes Trial, showed a 15% reduction of relative risk in non-fatal MI with every 1% decrease in HbA1c.[@R61] A retrospective cohort study reported that medication adherence was associated with better glycaemic control by one and a half folds when compared with non-adherent patients.[@R62] Not surprisingly, poor adherence to OADs was associated with poor glycaemic control as documented by many published studies.[@R63] This study reported that around two-thirds of patients with T2DM failed to achieve adequate glycaemic control, which is consistent with another published study in Saudi Arabia,[@R65] but had higher than the average global HbA1c levels reported in the literature (45%).[@R66] However, no significant association between achieving glycaemic control and adherence level was seen in this study.

Poor glycaemic control due to non-adherence to OADs can lead to higher microvascular complications (ie, nephropathy, [retinopathy](https://www.sciencedirect.com/topics/medicine-and-dentistry/retinopathy), and neuropathy),[@R67] higher macrovascular complications (ie, MI and ischaemic stroke)[@R68] and high risk of mortality,[@R68] hospitalisation and emergency department visits.[@R16] Besides, poor glycaemic control due to non-adherence to OADs can lead to an increased diabetes care cost. In the USA, non-adherence to diabetes medications cost \$337 billion in 2013.[@R17] In Saudi Arabia, the economic burden of T2DM compliance and persistence for patients who struggle to achieve optimal therapy is estimated around 3.9 billion Saudi Riyals (US\$1.04 billion) and the cost is expected to significantly increase in the future.[@R69] The value of adherence to pharmacologic treatments in achieving and controlling diabetes has clearly been established. Good adherence can mitigate the risk of hospitalisation, emergency room visits,[@R70] all-cause mortality[@R71] and could improve the overall glycaemic control.[@R15]

Strengths and limitations {#s5d}
-------------------------

Adherence can be measured by different methodological approaches. In this study, adherence was assessed using the mMPR method, which is a reliable method and depends on real-world data obtained from patient's medication refill history. This method can be used for a large population at a relatively low cost and also prevents recall bias, which is associated with patient interview-based adherence methods. This study sheds some light into concomitant diseases that were associated with OADs non-adherence. Although the current study provides real-world information from more than 5400 patients about adherence rate to different OADs and the relationship of OADs and glycaemic control, few limitations were observed. The study population was mostly patients who attended the KSUMC in central Saudi Arabia; therefore, it is difficult to extrapolate the study findings to the whole Saudi population residing in the other geographical areas of the country. Nevertheless, patients included in this study represent almost all Saudi citizens and expatriate groups living in Saudi Arabia. In addition, important information, such as health literacy, educational level, economic status, marital status, knowledge about disease and medications thatmight be contributing factors to medication non-adherence, was not available from EHRs. It should be noted that the adherence in this study was based on pharmacy refills data, which only indicates the possession of the medication, but does not capture the actual consumption of the medication by the patient. This is one of the limitations in calculating adherence using pharmacy refills data as it assumes that the medication was actually taken by the patient, which may not necessarily be the case. The main advantage of using the EHRs is the availability of large sample size that can provide precise estimates and availability of dispensing date and quantity dispensed, which is hard to collect from the patients using the patient-reported measures. Other tools that potentially provide more accurate estimation about the actual consumption and adherence include direct measures such as measurement of drug of metabolite in body fluids or testing for biomarkers. However, these are expensive and intrusive to patients and therefore difficult to implement.

Future implications {#s5e}
-------------------

Healthcare professionals have to pay special attention to patients with diabetes, especially those with polypharmacy and concomitant diseases, as this will increase the risk for non-adherence to OADs medication. Although we have few patients with medication oversupply in our study, it is worthwhile for healthcare providers and policymakers to be aware of this important issue and to plan for a strategy to prevent both under/over-supply of medications. Further investigations are needed to explore the oversupply across different populations and chronic diseases as the rate could vary significantly. This will allow the estimation of financial loss due to medication oversupply (eg, wastage) and can help implement effective strategies to prevent medication oversupply. In addition, our findings indicated a surprising result regarding the adherence in female with OADs in patient with T2DM, thereby identifying a need to investigate the factors affecting adherence to OADs among females.

Clinical practice implications {#s5f}
------------------------------

Healthcare providers must remain vigilant when evaluating adherence to OADs medications, by counselling patients at each visit and properly assessing medication adherence as a behaviour. Improving patient-clinician relationships, providing information to guide self-management to support patients with diabetes can provide a clinically significant improvement in glycaemic control for some patients and improve other health outcomes. As medication oversupply was an issue in our study especially among those with comorbid chronic conditions and those with multiple medications, pharmacy services such as reconciliation and medication therapy management are needed to optimise medication use.

Conclusions {#s6}
===========

The study findings support the growing concern of non-adherence to OADs among patients with T2DM in Saudi Arabia. Both providers and pharmacists, in their interaction with the patients, should stress on the importance of adherence and its impact on clinical, economic and humanistic outcomes and also focus on preventive measures such as lifestyle modifications. Decision makers have to invest in behavioural interventions such as motivational interviewing, planned behaviour education and problem-solving training which can boost the adherence rates to medications and reduce medication oversupply.[@R73] This is particularly important in patients with polypharmacy or hyperpolypharmacy and high burden of comorbid conditions.
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